Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C24H29N5O4 |
| Molecular Weight | 451.5182 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)CCC(=O)N(CC1=CC=C(C=C1)C2=C(C=CC=C2)C3=NN=NN3)[C@@H](C(C)C)C(O)=O
InChI
InChIKey=ICSQZMPILLPFKC-XLDIYJRPSA-N
InChI=1S/C24H29N5O4/c1-15(2)22(24(32)33)29(21(31)13-8-16(3)30)14-17-9-11-18(12-10-17)19-6-4-5-7-20(19)23-25-27-28-26-23/h4-7,9-12,15-16,22,30H,8,13-14H2,1-3H3,(H,32,33)(H,25,26,27,28)/t16?,22-/m0/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. | 2004 May |
|
| Biovalidation of an SPE-HPLC-UV-fluorescence method for the determination of valsartan and its metabolite valeryl-4-hydroxy-valsartan in human plasma. | 2007 Sep |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
N891C54AXX
Created by
admin on Sat Dec 16 00:26:05 GMT 2023 , Edited by admin on Sat Dec 16 00:26:05 GMT 2023
|
PRIMARY | |||
|
9911647
Created by
admin on Sat Dec 16 00:26:05 GMT 2023 , Edited by admin on Sat Dec 16 00:26:05 GMT 2023
|
PRIMARY | |||
|
188259-69-0
Created by
admin on Sat Dec 16 00:26:05 GMT 2023 , Edited by admin on Sat Dec 16 00:26:05 GMT 2023
|
PRIMARY |
PARENT (METABOLITE INACTIVE)
SUBSTANCE RECORD
